Announcements

Strategy Inc filed an 8-K current report on September 14, 2026, disclosing its bitcoin holdings, at-the-market offering activity, share repurchase activity, and USD reserve balances for the period September 8 through September 13, 2026.

Piedmont Realty Trust, Inc. filed a Form 8-K on September 14, 2026, disclosing an office acquisition in Arlington, Virginia, two completed or pending property dispositions, and a proposed $200,000,000 private offering of exchangeable senior notes through its operating partnership.

Scholar Rock Holding Corporation filed a Form 8-K on September 14, 2026, reporting that the U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older who are currently receiving …

Cabaletta Bio, Inc. filed a current report on September 14, 2026 disclosing the final exercise results for Common Stock Warrants issued in its June 2025 underwritten public offering, with aggregate gross proceeds from all exercises totaling approximately $128.2 million.

A Form 4 filed on September 14, 2026, reports that Daniel Karlin, Chief Medical Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), acquired 200,000 common shares at $0.00 as the third tranche of a performance share unit grant, bringing his total beneficial ownership to 803,699 shares.

Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), filed a Form 4 on September 14, 2026, reporting the acquisition of 125,000 common shares through the vesting of performance share units.

NETSTREIT Corp. filed a Form 8-K with the U.S. Securities and Exchange Commission on September 14, 2026, disclosing under Item 7.01 (Regulation FD) that it released an investor presentation intended for use in meetings with investors.